1 2008 EMEA / IFAH–Europe Info Day « Balancing the benefits and risks of Veterinary Medicinal Products »

Slides:



Advertisements
Similar presentations
Overview of Risk management: A EU perspective Lincoln Tsang May 2008.
Advertisements

Session 6 : Need for good governance Importance of veterinary legislation and its appropriate implementation Jean-Luc ANGOT, CVO, France 14 March 2013.
World Veterinary Association Dr.Tjeerd Jorna President Presentation African Veterinary Association September 2009.
Safety Reporting IN Clinical Trials
“One Health” pulling Animal Health and Public Health together
EU-funded Digital Preservation Research APA 2014 Conference Brussels, 22 October 2014 Dr. Manuela Speiser European Commission DG CONNECT, unit "Creativity"
Disclaimer The presentation is intended for educational purposes only and does not replace independent professional judgement. Statements of fact and opinions.
The Scale, Causes and Costs of Medicines Waste – a national perspective Northamptonshire Medicine Waste Management Conference, 28 th November 2012 David.
AGENCY FOR PREVENTION OF CORRUPTION AND COORDINATION OF FIGHT AGAINST CORRUPTION mr.sci. Vladica Babić - Assisstent.
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
OIE Global Conference on Veterinary Education and the Role of VSB Foz do Iguazu, Brazil – 4-6 December By Tjeerd Jorna – WVA Immediate Past President.
7 1 FVE General Assembly Agenda point 10: EU Community Animal Health Strategy Brussels, 16 November 2007.
Clinical Pharmacy Basma Y. Kentab MSc..
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Capacity building activities of the OIE STDF WORKSHOP on Capacity Building Tools Geneva, 31 March 2008 Dr Sarah Kahn Director, International Trade Department.
1 Science and Society: EU Strategy and actions Dr. Rainer GEROLD Director Science and Society Research DG European Commission.
 Pharmacovigilance – Patient’s standpoint Steve Arlington May 2007.
EFSA MANAGEMENT PLAN 2008 The Management Plan
Cross Border Animal Health Plan of Action – Kenya and Uganda Four Strategic areas 1. To improve prevention, management and control of cross border animal.
1 SIM Directive (Services in the Internal Market) & European Code of Conducts 12 September 2007.
Benefits of a strong collaboration with patient groups at national and EU level Susanna Palkonen, Director European Federation.
Application in professional activity of theoretical knowledge and practical skills acquired during residency program Dr. Ion Bîrcă National Center of Public.
The Human-Animal Bond Veterinary Medical Applications.
Chapter #1 Important Points. Being in the best of health throughout your life means making healthy choices and practicing healthful behaviors.
FAO’S Development Law Service Law and Development at FAO “Sound legal frameworks are essential to achieving sustainable agricultural development and effective.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
A major step towards a Europe for Health Directive on patients’ rights in cross-border healthcare DG SANCO D2 Healthcare Systems.
1 OIE CAPACITY BUILDING ACTIVITIES Regional Information Seminar for Recently Appointed OIE Delegates 18 – 20 February 2014, Brussels, Belgium Dr Mara Gonzalez.
 Definition of Saunders Comprehensive Veterinary Dictionary: => "the avoidance of abuse and exploitation of animals by humans by maintaining appropriate.
PERFORMANCE OF VETERINARY STATUTORY BODIES CURRENT SITUATION AND EVOLUTION IN BRAZIL.
Department of Health and Human Services Office of the Assistant Secretary for Health (ASH) Advisory Committee on Blood Safety and Availability (ACBSA)
1 OIE Global Conference on Veterinary Education and the role of Veterinary Statutory Body 4 – 6 December 2013 Foz do Iguazu (Brazil)
METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.
Health Information and Knowledge EU Public Health Portal E Health conference 24 May 2005 Trömso John F. Ryan Head of Unit Unit C2 – Health Information.
HTA Benefits and Risks Dr Bernard Merkel European Commission.
LMI Learning module – Overview © Institute for Employment Research, University of Warwick.
Minimum requirements for Pharmacovigilance in countries.
Component II: Linking quality of Veterinary Services to progressive control of PPR Nadège Leboucq (OIE) On behalf of the GF-TADs PPR Working Group First.
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
Future needs for capacity building and recommendations to the OIE Dr Sarah Kahn Consultant to the OIE
PharmacoVigilance: Development of PhV systems and processes.
1 Education in Animal Welfare: why, for who, how, when and by whom? David B.Morton University of Birmingham FAWC/EFSA.
1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.
World Health Organization Department of Chronic Diseases and Health Promotion World Health Organization Strengthening Institutions: Indicators for Measuring.
PharmacoVigilance: Development of PhV systems and processes VICH Workshop, Dar Es Salaam, Tanzania, 24 June 2015.
1 ENFORCEMENT OF EUROPEAN, ANIMAL WELFARE RELATED LEGISLATION Brussels, 12 – 13 June 2012.
1 Pharmacovigilance & the New National Adverse Drug Reaction (ADR) Reporting System Michael Bonett, Quality Assessor Post-Licensing Directorate Medicines.
1 The EU’s efforts to provide high quality and safe Organ transplantation Anna Pavlou European Commission Health and Consumers Directorate General Public.
The Need to Improve Quality of Nursing care, Patient’s Safety and Evidence-Based Practice in Saudi Arabia Dr Abbas Al Mutair Ph.D, MN, BN, CCN Post Grad.
Western Balkans Veterinary Network ‘Western Balkans Veterinary Network’- advancing animal welfare through education, research and professional training.
1 The contribution of VICH to the global One Health approach VICH5 CONFERENCE, OCTOBER 2015, TOKYO Jean-Pierre Orand, Anses, France, OIE Collaborating.
Jacques McMillan Has Accreditation fulfilled the expectations? Jacques McMillan Former European.
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
A capacity building programme for patient representatives
Principles of Risk Management
Efficacy and Safety of Medicines
Veterinary Obligations to the Animal Kingdom
Component 11/Unit 7 Implementing Clinical Decision Support
TAIEX, Istanbul, April 19th, 2011
World Organisation for Animal Health (OIE)
Seminar for National Delegates to the OIE: “Development of public–private partnerships to support Veterinary Services” 10 November 2015, Kaslik.
World Organisation for Animal Health
Helen Lee, European Commission
Wednesday 16 May 2018 Zagreb, Croatia
World Organisation for Animal Health
Identification as a guarantee for proper vaccination and animal health Brussels June 2016 Nancy De Briyne, FVE Ann Criel, FECAVA Federation of.
World Organisation for Animal Health
Pharmacovigilance updates
Raising the bar Meeting Europe’s future challenges
Communication & Technology Research
Presentation transcript:

EMEA / IFAH–Europe Info Day « Balancing the benefits and risks of Veterinary Medicinal Products »

2 Update on Pharmacovigilance Perspective of the veterinary practitioner

3 FVE is a Federation of 42 veterinary organisations in 37 European countries Through its members, FVE represents approximately veterinarians

4 FVE’s objective Representing the Veterinary Profession at the European level in order to: Promote veterinary medicine Support veterinarians in delivering their services and their responsibilities towards our societies

5 Animals Owners / Keepers Society v Science Knowledge / Skills Ethics / Attitude Objective Independent Impartial

6 benefits / risk of vmps cost / benefits of monitoring system

7 VMPs are very important tools in the prevention and control of animal diseases Veterinary practitioners would like to have broad range of products for all species and indications (incl MUMS) that are reliable i.e. have a good and predictable efficacy and safety

8 Veterinarians believe that current product safety and efficacy evaluations required for obtaining a marketing authorisation and batch tests are solid

9 Veterinary practitioners see the need for continuous monitoring of vmps under field conditions ! To have a better understanding of the product To be re-assured that a product is efficacious and safe To be alerted in case something goes wrong or

10 Adverse effects are unwanted, especially in case they were not foreseen they are serious and / or long-lasting where groups of animals are involved where the owner is worried

11 Reasons for veterinary practitioners to report (suspected) product failure Ethical and legal obligation Prevention of future cases (general interest) For compensation of damage (per case)

12 Veterinarians are more motivated to report adverse effects, when they see an added value: –when they encounter something new –when it is considered a serious case –when it does not cause too much extra work – preferably on-line reporting –when they get feedback on the report –when the owner of the animal complains

13 Balancing risk / benefits of vmps Normal authorisation procedure By CA for immunologicals in the event of serious epizootic diseases Post marketing surveillance / Pharmacovigilance By veterinary practitioner case by case

14 Balancing the monitoring system Veterinary practitioners wish to have limited administrative procedures (simple as possible) get feedback on indivisual cases get feedback on the system / trends (make it visible) avoid disproportionate concerns about possible adverse reactions

15 How far do we want to go? What are the priorities? What is proportionate? –In relation to the effect as such –In relation to other Community animal health and welfare policies

16 Recommendation: a more intelligent use of the expertise available through the veterinary practitioners

17 “ Hominum Animaliumque Saluti” Thank you for your attention!

18 For Further information: Tel (+ 32)